세계의 마취 및 호흡기 장치 시장은 2024년에 540억 달러에 달하고, 2033년에는 939억 2,000만 달러에 이를 것으로 예측되고, 예측 기간 2025-2033년의 CAGR은 6.6%를 나타낼 전망입니다.
마취 및 호흡기 장치는 대 의료, 특히 수술 및 중환자 치료 상황에서 필수적인 요소입니다. 이러한 장치는 마취 또는 호흡 지원이 필요한 치료 중에 환자를 안전하고 편안하게 유지합니다. 마취 기기는 마취 가스와 산소의 제어된 혼합물을 환자에게 투여하는 의료 기기입니다. 이 장치는 수술 중 마취를 유도하고 유지하여 환자가 의식을 잃지 않고 통증을 느끼지 않는 상태를 유지하면서 필수 기능을 모니터링하고 지원할 수 있도록 도와줍니다. 호흡기 장치에는 스스로 충분히 호흡할 수 없는 사람의 호흡을 촉진하거나 조절하는 데 도움이 되는 다양한 장치가 포함됩니다. 여기에는 인공호흡기, 산소 전달 시스템 및 폐의 공기 흐름과 가스 교환을 제어하는 기타 장치가 포함됩니다.
마취 및 호흡기 장치에 대한 수요 증가는 예측 기간 동안 시장을 이끄는 원동력입니다. 기술 발전은 장치 효율성을 개선하고 호흡기 및 마취 매개 변수의 치료 및 진단에 도움이되는 마취 및 호흡기 장치에 대한 수요를 증가시킵니다. 예를 들어, 2024년 8월 프리바운스 헬스는 원격 환자 모니터링(RPM)을 위한 최초의 혈액 산소 기기인 Pylo OX1-LTE를 출시한다고 발표했습니다. 임상적으로 검증된 셀룰러 연결형 OX1-LTE는 만성 폐쇄성 폐질환(COPD) 또는 천식과 같은 만성 호흡기 질환 및 기타 다양한 시나리오에 대한 RPM 프로그램에 등록된 환자를 위해 다른 맥박 산소 측정기에 비해 많은 이점을 제공합니다.
촉진요인과 촉진요인
마취 및 호흡기 장치 수요 증가
마취 및 호흡기 장치에 대한 수요 증가는 세계의 마취 및 호흡기 장치 시장의 성장에 중요한 요인이 될 것으로 예상됩니다. 마취 및 호흡기 장치에 대한 수요 증가는 수술 건수 증가, 호흡기 질환 증가, 기술 발전, 최근 제품 출시 및 승인으로 인한 것입니다.
전 세계적으로 외과 수술 건수가 크게 증가했습니다. 수술 기술이 발전하고 선택적 수술이 보편화됨에 따라 의료진은 환자의 안전과 결과를 개선하기 위해 첨단 마취 및 호흡기 장치에 점점 더 의존하고 있습니다. 이러한 장치는 다양한 수술 과정에서 마취를 제공하고 기도 개통을 유지하며 호흡을 보조하는 데 중요한 역할을 합니다. 예를 들어, 미국 국립보건원에 따르면 미국의 수술률은 인구 10만 명당 12.0건에서 21.4건에 달합니다.
만성 폐쇄성 폐질환, 천식, 부비동염과 같은 만성 호흡기 질환이 전 세계적으로 확산됨에 따라 수술 및 중환자 치료 시 효과적인 관리를 위해 첨단 마취 및 호흡기 장치가 필요합니다. 예를 들어, 보건복지부에 따르면 전 세계 인구 20명 중 1명이 만성 호흡기 질환(CRD)을 앓고 있습니다. 동아시아 및 남아시아에서 만성 호흡기 질환으로 인한 사망률이 가장 높았습니다. 사회인구통계지수(SDI)가 낮은 중하위 국가들의 연령 표준화 CRD 사망률이 가장 높았습니다. 만성 호흡기 질환(CRD)에 대한 새로운 연구 결과에 따르면 만성 호흡기 질환은 전 세계적으로 약 400만 명이 사망하는 세 번째 주요 사망 원인으로 나타났습니다. 이 중 약 60%(약 2억 6,200만 명)가 천식 진단을 받아 가장 흔한 CRD로 나타났습니다. 1990년 이후 CRD의 신규 환자 수는 49.0% 증가했으며, 이는 주로 인구 증가에 기인합니다. 반면 연령 표준화 발병률은 5.3% 감소했습니다.
기술 발전은 시장 환경을 정의하는 데 중요한 역할을 합니다. 제조업체들은 더 나은 데이터 관리 및 모니터링을 통해 환자 치료를 개선하는 휴대용 및 네트워크 장치를 만드는 데 집중하고 있습니다. 최근에는 최신 기술을 사용하여 제조된 제품이 많이 출시되고 있습니다. 예를 들어, 2024년 7월, 에어리퀴드 메디컬 시스템은 기계식 인공호흡기의 획기적인 발전을 대표하는 최신 인공호흡기인 Monnal TEO를 출시했습니다. 이 인공호흡기는 특히 중환자실과 중환자실에서 사용하기 위한 것으로, 급성 호흡 부전 상태의 환자 치료를 개선하기 위한 노력을 보여줍니다.
따라서 수술 건수의 증가, 호흡기 질환의 증가, 기술 발전으로 인해 마취 및 호흡기 장치에 대한 수요가 급증하고 시장을 주도하고 있습니다.
장치의 높은 비용
장치의 비용이 높은 등의 요인이 세계의 마취 및 호흡 장치 시장을 저해할 것으로 예상됩니다. 높은 비용의 가장 중요한 이유 중 하나는 첨단 마취 및 호흡 장치를 생산하기 어렵다는 점입니다. 이러한 기기에는 인공 지능 및 복잡한 모니터링 시스템과 같은 최첨단 기술이 포함되어 있는 경우가 많기 때문에 R&D에 상당한 투자가 필요합니다. 또한 제조업체는 제품이 안전 및 효능 요건을 충족하는지 확인해야 하기 때문에 높은 규제 표준을 준수하면 생산 비용이 증가합니다. 예를 들어, 미국 국립보건원에 따르면 기본 사례 환자에게 장기간 기계적 인공호흡(PMV)을 제공하는 경우 인공호흡을 중단하는 경우와 비교했을 때 수명 연한 증가당 $55,460, 질 보정 수명 연한(QALY) 당 $82,411의 비용이 발생합니다. 특히 PMV 조항에 따라 QALY당 증가된 비용은 10만 달러를 넘어섰습니다.
The global anesthesia and respiratory devices market reached US$ 54 billion in 2024 and is expected to reach US$ 93.92 billion by 2033, growing at a CAGR of 6.6% during the forecast period 2025-2033.
Anesthesia and respiration devices are vital in contemporary healthcare, especially in surgical and critical care scenarios. These devices keep patients safe and comfortable during treatments that need anesthesia or breathing support. Anesthesia devices are medical devices that administer a controlled mixture of anesthetic gases and oxygen to patients. This equipment aids in the induction and maintenance of anesthesia during surgical procedures, allowing patients to remain unconscious and painless while their essential functions are monitored and supported. Respiratory devices include a variety of equipment that helps facilitate or control breathing for individuals who are unable to breathe sufficiently on their own. This includes ventilators, oxygen delivery systems, and other devices that control airflow and gas exchange in the lungs.
The increasing demand for anesthesia and respiratory devices is the driving factor that drives the market over the forecast period. The technological advancements improve the device efficiency and increase the demand for anesthesia and respiratory devices which helps in the treatment and diagnosis of respiratory and anesthesia parameters. For instance, in August 2024, Prevounce Health announced the launch of its first blood oxygen device for remote patient monitoring (RPM) Pylo OX1-LTE. The clinically validated, cellular-connected OX1-LTE offers numerous advantages over other pulse oximeters for patients enrolled in RPM programs for chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD) or asthma, and a variety of other scenarios.
Market Dynamics: Drivers & Restraints
Increasing demand for anesthesia and respiratory devices
The increasing demand for anesthesia and respiratory devices is expected to be a significant factor in the growth of the global anesthesia and respiratory devices market. The increasing demand for anesthesia and respiratory devices is due to an increasing number of surgical procedures, an increasing number of respiratory disorders, technological advancements, recent product launches, and approvals.
There has been a significant increase in the number of surgical procedures performed internationally. Healthcare practitioners are increasingly depending on advanced anesthetic and respiratory devices to improve patient safety and results as surgical techniques evolve and elective surgeries become more common. These devices play an important role in providing anesthetic, preserving airway patency, and assisting breathing during various surgical procedures. For instance, according to the National Institute of Health, Surgical rates in the United States ranged from 12.0 to 21.4 surgeries per 100,000 people.
As chronic respiratory conditions like COPD, asthma, and sinusitis become more prevalent globally, advanced anesthesia and respiratory devices are necessary for effective management during surgeries and critical care. For instance, according to the Department of Health & Human Services, 1 in 20 people globally suffers from chronic respiratory disease (CRD). East Asia and South Asia had the highest rates of CRD mortality. Low-middle and low Socio-demographic Index (SDI) countries had the highest age-standardized rates of CRD deaths. New findings on chronic respiratory disease (CRD) now show it is the third leading cause of death globally, accounting for approximately 4 million deaths worldwide. Asthma was diagnosed in approximately 60% of these people (approximately 262 million), making it the most common CRD. Since 1990, the number of new cases of CRDs has increased by 49.0%, owing primarily to population growth. The age-standardized incidence rate, on the other hand, has decreased by 5.3%.
Technological advancements play an important part in defining the market landscape. Manufacturers are concentrating on creating portable and networked equipment that improves patient care through better data management and monitoring. In recent times, there have been many product launches that are manufactured using the latest technology. For instance, in July 2024, Air Liquide Medical Systems launched its latest ventilator, Monnal TEO, which represents a substantial advancement in mechanical ventilation. This ventilator is specifically intended for use in intensive care and critical care units, indicating a commitment to improving patient care in acute respiratory failure conditions.
So, the increasing number of surgical procedures, an increasing number of respiratory disorders, and technological advancements upsurge the demand for anesthesia and respiratory devices and drive the market.
High costs of devices
Factors such as high costs of devices are expected to hamper the global anesthesia and respiratory devices market. One of the most significant reasons for the high costs is the difficulty of producing advanced anesthetic and respiratory devices. These gadgets frequently contain cutting-edge technologies, such as artificial intelligence and complex monitoring systems, which necessitate significant investment in R&D. Additionally, compliance with high regulatory standards raises production costs since manufacturers have to ensure that their products meet safety and efficacy requirements. For instance, according to the National Institute of Health, Providing prolonged mechanical ventilation (PMV) to the base-case patient costs $55,460 for every life-year gain and $82,411 per quality-adjusted life year (QALY) when compared to stopping ventilation. Specifically, the incremental costs per QALY gained under the PMV provision topped $100,000.
The global anesthesia and respiratory devices market is segmented based on respiratory equipment, respiratory disposables, respiratory measurement devices, anesthesia machines, anesthesia disposables, end-user, and region.
Oxygen concentrator segment is expected to dominate the global anesthesia and respiratory devices market share
The oxygen concentrator segment is anticipated to dominate the global anesthesia and respiratory devices market due to a number of compelling factors. Oxygen concentrators are widely recognized for their crucial function in providing oxygen supplementation to patients with respiratory diseases. This segment's expansion is primarily driven by the increased prevalence of chronic respiratory disorders, an aging population, and technological improvements that improve the efficiency and effectiveness of these devices.
The number of cases of respiratory disorders is increasing these days due to various factors such as smoking, exposure to air pollution, allergens, and occupational hazards. For instance, according to the American Lung Association, COPD affects 11.7 million adults, resulting in hundreds of thousands of emergency department visits and tens of billions of dollars in healthcare expenses each year. Moreover, according to the Cystic Fibrosis Foundation, Cystic fibrosis affects about 40,000 children and adults in the United States (an estimated 105,000 people have been diagnosed with the disease in 94 countries), and it can affect people of any ethnic background. So, oxygen concentrators play a vital role in providing oxygen supplementation and the demand for oxygen concentrators increases due to increasing respiratory disorders.
Technological advancements have also played a significant part in increasing the demand for oxygen concentrators. Compact designs, lightweight simulations, and user-friendly interfaces have improved the accessibility and usability of these gadgets. For example, portable oxygen concentrators give patients more mobility to engage in daily activities without being attached to fixed equipment. There are recent product launches that use novel technology. For instance, in January 2024, Belluscura, a medical device developer focused on lightweight and portable oxygen enrichment technology, received approval from the Singapore Health Sciences Authority to distribute the X-PLOR portable oxygen concentrator in Singapore.
The use of oxygen concentrators in anesthesia provides greater flexibility and efficiency in controlling patient care. In an emergency or during a power outage, POCs can be used as a backup oxygen source for anesthetic machines, preventing hypoxia and maintaining continuous ventilation. The increasing prevalence of respiratory disorders, technological advancements, and recent product launches and approvals upsurged the demand for oxygen concentrators making this segment the most dominating.
North America is expected to hold a significant position in the global anesthesia and respiratory devices market share
The dominance of the North American market in the global anesthesia and respiratory devices market is due to various factors such as advanced healthcare infrastructure, high prevalence of respiratory diseases, strategic partnerships, product launches and approvals, and increasing adoption of innovative medical technologies.
The increasing prevalence of respiratory disorders in this region increases the demand for respiratory devices. For instance, according to health.gov, respiratory diseases affect millions of people in the United States. More than 25 million people in the United States have asthma. Strategies to reduce environmental triggers and make sure people get the right medications can help prevent hospital visits for asthma. In addition, more than 16 million people in the United States have COPD (chronic obstructive pulmonary disease), which is a major cause of death. Strategies to prevent the disease, like reducing air pollution and helping people quit smoking are key to reducing deaths from COPD.
Due to the presence of top players in this region, strategic partnerships take place to improve the efficiency of various medical devices. For instance, in June 2024, Novair and American Oxygen announced a strategic partnership to develop and market ionic oxygen generators, set to revolutionize the oxygen market. As part of this strategic partnership, Novair will acquire an equity stake in American Oxygen, and the partners will set up a joint venture dedicated to the manufacture of ionic oxygen generators.
In the US, there are recent product launches of anesthesia devices. For instance, in June 2024, SOMNOmedics AG launched its latest anesthesia depth monitoring tool. The NARCOguide is a small and compact stand-alone gadget intended specifically for ambulatory environments. It may be readily mounted in the operation room using a bracket. The device is controlled using the integrated touch display. The display clearly demonstrates all data at a glance, including depth of anesthesia and blood pressure curves for progress control, current depth of anesthesia values, automatic burst suppression detection, oxygen saturation, heart rate, and blood pressure, as well as raw EEG and ECG data.
Asia Pacific is growing at the fastest pace in the global anesthesia and respiratory devices market
The Asia Pacific region is emerging as the fastest-growing market for anesthesia and respiratory devices, owing to a combination of demographic trends, increased healthcare investment, recent launches, an increasing number of surgical procedures, and an increasing prevalence of respiratory diseases.
The increasing prevalence of respiratory diseases is one of the factors that drive the market in this region. For instance, according to The International Primary Care Respiratory Group, India has one of the highest rates of chronic respiratory illness. India accounts for 15.69% of worldwide chronic respiratory diseases, whereas 30.28% of all global deaths from chronic respiratory diseases occur in India. India has the world's greatest number of COPD (Chronic Obstructive Pulmonary Disease) cases, totaling 55.23 million. India has the second-highest number of COPD-related deaths globally, accounting for almost 0.85 million.
There are recent product launches of anesthesia devices in this region. For instance, according to an article published by the Times of India in June 2024, Renowned Indian data scientists have created a new AI-powered anesthetic monitoring system in India that will enable real-time, full analysis of physiological data during surgical procedures. The new AI-powered system uses machine learning algorithms to handle data from many sources, such as EEG, ECG, and pulse oximetry, assuring accurate and timely monitoring.
The major global players in the global anesthesia and respiratory devices market include GE HealthCare, Medtronic, Teleflex Incorporated, Koninklijke Philips N.V., Dragerwerk AG & Co. KGaA, Getinge AB, Smiths Group plc, Fisher & Paykel Healthcare Limited., ResMed, Inogen, Inc. among others.
Emerging Players
Aerin Medical, Circadia Health, and SeaStar Medical among others
The global anesthesia and respiratory devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE